Respiratory Function Changes as Early Signs of Amyotrophic Lateral Sclerosis

Authors

Mario Polverino
Simone Sampaolo
Antonio Capuozzo
Marco Fasolino
Michele Aliberti
Ersilia Satta
Carlo Santoriello
James Peter Orengo
Francesca Polverino

Publication Date

1-1-2023

Journal

Respiration

DOI

10.1159/000533870

PMID

37844546

PMCID

PMC10842422

PubMedCentral® Posted Date

10-16-2024

PubMedCentral® Full Text Version

Author MSS

Published Open-Access

yes

Keywords

Humans, Amyotrophic Lateral Sclerosis, Respiration, Respiratory Function Tests, Lung, Exhalation, ALS, diagnosis, respiratory drive, pulmonary function, muscle weakness

Abstract

BACKGROUND: The current diagnostic criteria for amyotrophic lateral sclerosis (ALS) may remain unsatisfactory for months or years in the early disease. Pulmonary assessment has never been considered useful in the early diagnosis of ALS, and studies of pulmonary function in this patient category are lacking.

OBJECTIVES: The objective of this study was to assess the pulmonary function in subjects with unspecific symptoms of ALS in whom an ALS diagnosis cannot be reached based on the current available guidelines.

METHODS: We performed pulmonary function tests, arterial gas analysis, maximal inspiratory (MIP) and expiratory (MEP) pressure, and respiratory drive (P0.1) assessment in 35 patients with unspecific neurological symptoms at the time of the visit and those were subsequently diagnosed with ALS 2 years after the initial visit ("pre-ALS"); we compared these patients with 29 patients with established ALS and with 28 control subjects.

RESULTS: Spirometric parameters were not different between the three groups. However, MIP was significantly lower and P0.1 was significantly increased (with the ratio P0.1/MIP significantly higher) in both established and pre-ALS patients compared to controls, while both MIP and P0.1 were similar between established ALS and pre-ALS.

CONCLUSIONS: Changes in MIP, P0.1, and P0.1/MIP ratio are highly suggestive of preclinical ALS when the spirometry and neurodiagnostic tests are still inconclusive. MIP and P0.1 are noninvasive measurements that can be easily assessed in an ambulatory setting. Future studies on larger cohorts are needed to validate the use of these parameters in the preclinical diagnosis of ALS as well as in other neuromuscular diseases.

Comments

Associated Data